Gradual withdrawal of remifentanil delays initial post-operative analgesic demand after thyroid surgery; double-blinded, randomized controlled trial
Sarah Saxena, Kimberly Gonsette, Willy Terram, Isabelle Huybrechts, Daniel A Nahrwold, Matteo Cappello, Luc Barvais, Edgard Engelman, Sarah Saxena, Kimberly Gonsette, Willy Terram, Isabelle Huybrechts, Daniel A Nahrwold, Matteo Cappello, Luc Barvais, Edgard Engelman
Abstract
Background: Mismanagement of remifentanil leads to severe side effects such as opioid-induced tolerance and hyperalgesia. Recently studies revealed an alternative withdrawal method to limit these side effects. A gradual withdrawal of remifentanil seems to be associated with less pain. The hypothesis of this double-blinded, randomized controlled trial was that a gradual withdrawal of remifentanil would be associated with less immediate post-operative pain compared to after an abrupt discontinuation of remifentanil in patients who underwent thyroid surgery.
Methods: This double-blinded, randomized controlled trial was conducted in a tertiary level hospital in Brussels (Belgium) from April until August 2017. 34 patients undergoing thyroid surgery were randomized and 29 patients completed the study. After randomization, patients undergoing thyroid surgery were allocated to two groups: one with an abrupt discontinuation of remifentanil after surgery and one with a gradual withdrawal of remifentanil after surgery. The primary outcome was the initial post-operative demand of analgesic medication.
Results: Gradual withdrawal of remifentanil was associated with a delayed initial post-operative demand of analgesic medication (P = 0.006). The first morphine bolus was given after 76.3 +/- 89.0 min in the group with a gradual withdrawal of remifentanil versus after 9.0 +/- 13.5 min in the group with an abrupt discontinuation of remifentanil. However, overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) were similar in both groups (P > 0.05).
Conclusion: Though overall morphine consumption, numeric rating scale scores, Ramsay Sedation Scale scores, and quality of recovery scores (QoR-40) are not altered, a gradual withdrawal of remifentanil after thyroid surgery is safe and associated with a delayed initial post-operative demand of analgesic drugs. The withdrawal process does, however, require vigilance and training.
Trial registration: Clinicaltrials.gov NCT03110653 (PI: Luc Barvais; date of registration: 03/31/2017).
Conflict of interest statement
Ethics approval and consent to participateThis study was approved by the internal review board (03/30/2017; P2017/074; Comité Ethique, Erasme hospital, Brussels; Chairman: Jean-Marie Boeymans). The trial was registered on clinicaltrials.gov (NCT03110653; PI: Luc Barvais; date of registration: 03/31/2017).
Written informed consent was obtained from each patient participating in the study.
Consent for publicationWritten informed consent was obtained from each patient participating in the study.
Competing interestsThe authors declare that they have no competing interests.
As of October 2017, SS is a recipient of a research fellowship of the Belgian American Education Foundation.
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- Fletcher D, Martinez V. Opioid induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112:991–1004. doi: 10.1093/bja/aeu137.
- Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409–417. doi: 10.1097/00000542-200008000-00019.
- Yu EHY, Tran HD, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long term pain? Anaesthesia. 2016;71:1347–1362. doi: 10.1111/anae.13602.
- Albrecht S, Fechner J, Geisslinger G, et al. Postoperative pain control following remifentanil-based anaesthesia for major abdominal surgery. Anaesthesia. 2000;55:315–322. doi: 10.1046/j.1365-2044.2000.01122.x.
- Didla R, Gassner M, Gingl E, Sandkuhler J. Induction of synaptic long-term potentiation after opioid withdrawal. Science. 2009;325:207–210. doi: 10.1126/science.1171759.
- Comelon M, Raeder J, Stubhaug A, Nielsen CS, Draegni T, Lenz H. Gradual withdrawal of remifentanil infusion may prevent opioid induced hyperalgesia. Br J Anaesth. 2016;116:524–530. doi: 10.1093/bja/aev547.
- Sprenger C, Eichler IC, Eichler L, Zollner C, Buchel C. Altered signaling in the descending pain modulatory system after short-term infusion of the mu-opioid agonist remifentanil. J Neurosci. 2018;38:2454–2470. doi: 10.1523/JNEUROSCI.2496-17.2018.
- Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000;84:11–15. doi: 10.1093/oxfordjournals.bja.a013366.
- Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxolone-alphadalone. BMJ. 1974;2:656–659. doi: 10.1136/bmj.2.5920.656.
- Sandkühler J, Gruber-Schoffnegger D. Hyperalgesia by synaptic long-term potentiation (LTP): an update. Curr Opin Pharmacol. 2012;12:18–27. doi: 10.1016/j.coph.2011.10.018.
- Richebé P, Cahana A, Rivat C. Tolerance and opioid-induced hyperalgesia. Is a divorce imminent. Pain. 2012;153:1547–1548. doi: 10.1016/j.pain.2012.05.002.
- Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–161.
- Richebé P, Pouquet O, Jelacic S, et al. Target-controlled dosing of remifentanil during cardiac surgery reduces postoperative hyperalgesia. J Cardiothorac Vasc Anesth. 2011;25:917–925. doi: 10.1053/j.jvca.2011.03.185.
Source: PubMed